Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

(Dollars in Millions Except Per Share Data)

<table>
<thead>
<tr>
<th></th>
<th>Second Quarter</th>
<th>Second Quarter</th>
<th>Six Months Ended</th>
<th>Six Months Ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2020</td>
<td>2019</td>
<td>2020</td>
<td>2019</td>
</tr>
<tr>
<td>Net Earnings, after tax- as reported</td>
<td>$3,626</td>
<td>$5,607</td>
<td>$9,422</td>
<td>$9,356</td>
</tr>
<tr>
<td><strong>Pre-tax Adjustments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intangible Asset Amortization expense</td>
<td>1,127</td>
<td>1,118</td>
<td>2,245</td>
<td>2,248</td>
</tr>
<tr>
<td>Litigation expense, net</td>
<td>613</td>
<td>409</td>
<td>733</td>
<td>832</td>
</tr>
<tr>
<td>IPR&amp;D</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>890</td>
</tr>
<tr>
<td>Restructuring related</td>
<td>115</td>
<td>142</td>
<td>233</td>
<td>232</td>
</tr>
<tr>
<td>Acquisition and Integration related ¹</td>
<td>29</td>
<td>55</td>
<td>(933)</td>
<td>122</td>
</tr>
<tr>
<td>Unrealized (gains)/losses on securities</td>
<td>(533)</td>
<td>(148)</td>
<td>(206)</td>
<td>(306)</td>
</tr>
<tr>
<td>Medical Device Regulation ²</td>
<td>37</td>
<td>-</td>
<td>51</td>
<td>-</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>(3)</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td><strong>Tax Adjustments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tax impact on special item adjustments ³</td>
<td>(253)</td>
<td>(230)</td>
<td>(520)</td>
<td>(763)</td>
</tr>
<tr>
<td>Tax legislation and related impacts</td>
<td>(324)</td>
<td>-</td>
<td>(434)</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted Net Earnings, after tax</td>
<td>$4,446</td>
<td>$6,950</td>
<td>$10,600</td>
<td>$12,611</td>
</tr>
<tr>
<td>Average shares outstanding (Diluted)</td>
<td>2,665.5</td>
<td>2,691.7</td>
<td>2,671.0</td>
<td>2,697.0</td>
</tr>
<tr>
<td>Adjusted net earnings per share (Diluted)</td>
<td>$1.67</td>
<td>$2.58</td>
<td>$3.97</td>
<td>$4.68</td>
</tr>
<tr>
<td>Operational adjusted net earnings per share (Diluted)</td>
<td>$1.69</td>
<td>$2.58</td>
<td>$3.97</td>
<td>$4.68</td>
</tr>
</tbody>
</table>

**Notes:**

¹ Acquisition and integration related costs for the six months of 2020 primarily includes a $983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.

² European Medical Device Regulation (MDR) costs represent one-time compliance costs for the Company's previously registered products. MDR is a replacement of the existing European Medical Devices Directive regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2021. The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations. The Company has excluded only external third-party regulatory and consulting costs from its Medical Devices operating segments' measures of profit and loss used for making operating decisions and assessing performance.

³ The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.
### Adjusted Operational Sales Growth
SECOND QUARTER 2020 ACTUAL vs. 2019 ACTUAL

#### Segments

<table>
<thead>
<tr>
<th></th>
<th>Consumer Health</th>
<th>Pharmaceutical</th>
<th>Medical Devices</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WW As Reported</strong></td>
<td>(7.0)%</td>
<td>2.1%</td>
<td>(33.9)%</td>
<td>(10.8)%</td>
</tr>
<tr>
<td>U.S.</td>
<td>1.3%</td>
<td>5.8%</td>
<td>(39.6)%</td>
<td>(8.3)%</td>
</tr>
<tr>
<td>International</td>
<td>(13.4)%</td>
<td>(2.4)%</td>
<td>(28.8)%</td>
<td>(13.4)%</td>
</tr>
<tr>
<td><strong>WW Currency</strong></td>
<td>(3.4)</td>
<td>(1.8)</td>
<td>(1.2)</td>
<td>(1.8)</td>
</tr>
<tr>
<td>U.S.</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>International</td>
<td>(6.0)</td>
<td>(3.8)</td>
<td>(2.4)</td>
<td>(3.8)</td>
</tr>
<tr>
<td><strong>WW Operational</strong></td>
<td>(3.6)%</td>
<td>3.9%</td>
<td>(32.7)%</td>
<td>(9.0)%</td>
</tr>
<tr>
<td>U.S.</td>
<td>1.3%</td>
<td>5.8%</td>
<td>(39.6)%</td>
<td>(8.3)%</td>
</tr>
<tr>
<td>International</td>
<td>(7.4)%</td>
<td>1.4%</td>
<td>(26.4)%</td>
<td>(9.6)%</td>
</tr>
<tr>
<td><strong>General Surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Advanced Sterilization Products</td>
<td></td>
<td></td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>U.S.</td>
<td></td>
<td></td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>International</td>
<td></td>
<td></td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Baby Care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baby Center</td>
<td>0.3</td>
<td></td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td>U.S.</td>
<td>0.7</td>
<td></td>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>International</td>
<td>0.0</td>
<td></td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td><strong>All Other Acquisitions and Divestitures</strong></td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>U.S.</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>International</td>
<td>(0.1)</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td><strong>WW Adjusted Operational</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>(3.4)%</td>
<td>3.9%</td>
<td>(32.5)%</td>
<td>(8.8)%</td>
</tr>
<tr>
<td>International</td>
<td>(7.5)%</td>
<td>1.5%</td>
<td>(26.1)%</td>
<td>(9.4)%</td>
</tr>
</tbody>
</table>

**Note:** Percentages are based on actual, non-rounded figures and may not sum
## Adjusted Operational Sales Growth

**SIX MONTHS 2020 ACTUAL vs. 2019 ACTUAL**

<table>
<thead>
<tr>
<th>Segments</th>
<th>Consumer Health</th>
<th>Pharmaceutical</th>
<th>Medical Devices</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S.</strong></td>
<td>0.9%</td>
<td>5.4%</td>
<td>(21.1)%</td>
<td>(3.8)%</td>
</tr>
<tr>
<td><strong>International</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>10.8%</td>
<td>7.2%</td>
<td>(23.1)%</td>
<td>(1.4)%</td>
</tr>
<tr>
<td>International</td>
<td>(6.8)%</td>
<td>3.2%</td>
<td>(19.2)%</td>
<td>(6.3)%</td>
</tr>
<tr>
<td><strong>WW Currency</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WW Currency</td>
<td>(2.7)</td>
<td>(1.6)</td>
<td>(1.3)</td>
<td>(1.6)</td>
</tr>
<tr>
<td>U.S.</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>International</td>
<td>(4.9)</td>
<td>(3.5)</td>
<td>(2.4)</td>
<td>(3.4)</td>
</tr>
<tr>
<td><strong>WW Operational</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WW Operational</td>
<td>3.6%</td>
<td>7.0%</td>
<td>(19.8)%</td>
<td>(2.2)%</td>
</tr>
<tr>
<td>U.S.</td>
<td>10.8%</td>
<td>7.2%</td>
<td>(23.1)%</td>
<td>(1.4)%</td>
</tr>
<tr>
<td>International</td>
<td>(1.9)%</td>
<td>6.7%</td>
<td>(16.8)%</td>
<td>(2.9)%</td>
</tr>
<tr>
<td><strong>Skin Health / Beauty</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Ci Labo - Japan</td>
<td>(0.2)</td>
<td></td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td>U.S.</td>
<td>0.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>International</td>
<td>(0.4)</td>
<td></td>
<td></td>
<td>(0.1)</td>
</tr>
<tr>
<td><strong>General Surgery</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Advanced Sterilization Products</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>1.0</td>
<td></td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td>International</td>
<td></td>
<td></td>
<td></td>
<td>0.4</td>
</tr>
<tr>
<td><strong>Baby Care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baby Center</td>
<td>0.3</td>
<td></td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td>U.S.</td>
<td>0.7</td>
<td></td>
<td></td>
<td>0.1</td>
</tr>
<tr>
<td>International</td>
<td>0.0</td>
<td></td>
<td></td>
<td>0.0</td>
</tr>
<tr>
<td><strong>All Other Acquisitions and Divestitures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>(0.1)</td>
<td>0.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>International</td>
<td>(0.2)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>WW Adjusted Operational</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S.</td>
<td>3.6%</td>
<td>7.0%</td>
<td>(18.8)%</td>
<td>(1.7)%</td>
</tr>
<tr>
<td>International</td>
<td>11.5%</td>
<td>7.2%</td>
<td>(22.0)%</td>
<td>(0.8)%</td>
</tr>
<tr>
<td></td>
<td>(2.5)%</td>
<td>6.7%</td>
<td>(15.9)%</td>
<td>(2.6)%</td>
</tr>
</tbody>
</table>

**Note:** Percentages are based on actual, non-rounded figures and may not sum
**Reconciliation of Non-GAAP Financial Measures**

<table>
<thead>
<tr>
<th></th>
<th>Consumer Health</th>
<th>Pharmaceutical</th>
<th>Medical Devices</th>
<th>Unallocated</th>
<th>Worldwide Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported Income Before Tax by Segment</td>
<td>$32</td>
<td>406</td>
<td>4,514</td>
<td>3,677</td>
<td>(354)</td>
</tr>
<tr>
<td>% to Sales</td>
<td>1.0%</td>
<td>11.5%</td>
<td>42.0%</td>
<td>34.9%</td>
<td>-8.3%</td>
</tr>
<tr>
<td>Intangible asset amortization expense</td>
<td>102</td>
<td>124</td>
<td>779</td>
<td>754</td>
<td>246</td>
</tr>
<tr>
<td>In-process research and development</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>Litigation expense, net</td>
<td>638</td>
<td>172</td>
<td>(58)</td>
<td>26</td>
<td>33</td>
</tr>
<tr>
<td>Unrealized loss/(gain) on securities</td>
<td>-</td>
<td>1</td>
<td>(522)</td>
<td>(151)</td>
<td>(11)</td>
</tr>
<tr>
<td>Restructuring related</td>
<td>20</td>
<td>37</td>
<td>21</td>
<td>19</td>
<td>74</td>
</tr>
<tr>
<td>Acquisition and integration related</td>
<td>-</td>
<td>-</td>
<td>10</td>
<td>51</td>
<td>19</td>
</tr>
<tr>
<td>Medical Device Regulation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>37</td>
</tr>
<tr>
<td>Other</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Adjusted Income Before Tax by Segment</td>
<td>$792</td>
<td>740</td>
<td>4,744</td>
<td>4,376</td>
<td>53</td>
</tr>
<tr>
<td>% to Sales</td>
<td>24.0%</td>
<td>20.9%</td>
<td>44.1%</td>
<td>41.6%</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

*Estimated as of 07/16/2020.*
Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Financial Measures

### Q2 YTD - Income Before Tax by Segment*

**Dollars in Millions**

<table>
<thead>
<tr>
<th></th>
<th>Consumer Health</th>
<th>Pharmaceutical</th>
<th>Medical Devices</th>
<th>Unallocated</th>
<th>Worldwide Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reported Income Before Tax by Segment</strong></td>
<td>$802</td>
<td>1,147</td>
<td>8,348</td>
<td>6,008</td>
<td>10,449</td>
</tr>
<tr>
<td><strong>% to Sales</strong></td>
<td>11.6%</td>
<td>16.7%</td>
<td>38.1%</td>
<td>28.9%</td>
<td>26.8%</td>
</tr>
<tr>
<td><strong>Intangible asset amortization expense</strong></td>
<td>202</td>
<td>-</td>
<td>1,550</td>
<td>1,561</td>
<td>2,245</td>
</tr>
<tr>
<td><strong>In-process research and development</strong></td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td><strong>Litigation expense, net</strong></td>
<td>638</td>
<td>180</td>
<td>35</td>
<td>351</td>
<td>733</td>
</tr>
<tr>
<td><strong>Unrealized loss/(gain) on securities</strong></td>
<td>1</td>
<td>(3)</td>
<td>(208)</td>
<td>(294)</td>
<td>(206)</td>
</tr>
<tr>
<td><strong>Restructuring related</strong></td>
<td>38</td>
<td>44</td>
<td>41</td>
<td>44</td>
<td>233</td>
</tr>
<tr>
<td><strong>Acquisition and integration related</strong></td>
<td>-</td>
<td>-</td>
<td>19</td>
<td>90</td>
<td>(933)</td>
</tr>
<tr>
<td><strong>Medical Device Regulation</strong></td>
<td>-</td>
<td>-</td>
<td>51</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td><strong>Adjusted Income Before Tax by Segment</strong></td>
<td>$1,681</td>
<td>1,571</td>
<td>9,785</td>
<td>8,650</td>
<td>12,581</td>
</tr>
<tr>
<td><strong>% to Sales</strong></td>
<td>24.3%</td>
<td>22.9%</td>
<td>44.7%</td>
<td>41.6%</td>
<td>32.2%</td>
</tr>
</tbody>
</table>

*Estimated as of 07/16/2020.
<table>
<thead>
<tr>
<th></th>
<th>Second Quarter</th>
<th>Intangible asset amortization</th>
<th>Litigation expense, net</th>
<th>In-process research and development</th>
<th>Restructuring related</th>
<th>Acquisition related</th>
<th>Unrealized (loss)/gain on securities</th>
<th>Medical Device Regulation</th>
<th>Tax legislation and related impacts</th>
<th>Other</th>
<th>Second Quarter</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>June 28, 2020</td>
<td>GAAP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-GAAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$ 6,579</td>
<td>[1,127]</td>
<td></td>
<td>(22)</td>
<td></td>
<td>(8)</td>
<td></td>
<td></td>
<td></td>
<td>$ 5,422</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Selling, marketing and admin expenses</td>
<td>4,993</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,987</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research and development expense</td>
<td>2,707</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,579</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (Income) / Expense</td>
<td>24</td>
<td>-</td>
<td>(613)</td>
<td>(32)</td>
<td>(24)</td>
<td>533</td>
<td></td>
<td>7</td>
<td>324</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-process research and development</td>
<td>6</td>
<td></td>
<td></td>
<td>(6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restructuring</td>
<td>61</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provision for taxes on income</td>
<td>314</td>
<td>217</td>
<td>123</td>
<td>22</td>
<td>4</td>
<td>(122)</td>
<td>7</td>
<td>324</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Net Earnings</td>
<td>3,626</td>
<td>910</td>
<td>490</td>
<td>93</td>
<td>25</td>
<td>(411)</td>
<td>30</td>
<td>(324)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,446</td>
</tr>
<tr>
<td></td>
<td>Second Quarter</td>
<td>Intangible asset amortization</td>
<td>Litigation expense, net</td>
<td>In-process research and development</td>
<td>Restructuring related</td>
<td>Acquisition related</td>
<td>Unrealized (loss)/gain on securities</td>
<td>Medical Device Regulation</td>
<td>Tax legislation and related impacts</td>
<td>Other</td>
<td>Second Quarter</td>
</tr>
<tr>
<td></td>
<td>June 30, 2019</td>
<td>GAAP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-GAAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$ 6,940</td>
<td>[1,080]</td>
<td></td>
<td>(38)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (Income) / Expense</td>
<td>(1,683)</td>
<td>(38)</td>
<td>(409)</td>
<td>(47)</td>
<td>(55)</td>
<td>148</td>
<td></td>
<td>(2,081)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restructuring</td>
<td>57</td>
<td></td>
<td>(57)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provision for taxes on income</td>
<td>1,434</td>
<td>139</td>
<td>67</td>
<td>26</td>
<td>5</td>
<td>(31)</td>
<td>24</td>
<td>1,664</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Net Earnings</td>
<td>5,607</td>
<td>979</td>
<td>342</td>
<td>116</td>
<td>50</td>
<td>(117)</td>
<td>(27)</td>
<td>6,950</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Six Months</td>
<td>Intangible asset amortization</td>
<td>Litigation expense, net</td>
<td>In-process research and development</td>
<td>Restructuring related</td>
<td>Acquisition related</td>
<td>Unrealized (loss)/gain on securities</td>
<td>Medical Device Regulation</td>
<td>Tax legislation and related impacts</td>
<td>Other</td>
<td>Six Months</td>
</tr>
<tr>
<td></td>
<td>June 28, 2020</td>
<td>GAAP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>June 28, 2020</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$ 13,641</td>
<td>[2,240]</td>
<td></td>
<td>(37)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GAAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Selling, marketing and admin expenses</td>
<td>10,196</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10,190</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Research and development expense</td>
<td>5,287</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,259</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (Income) / Expense</td>
<td>(6,655)</td>
<td>-</td>
<td>(733)</td>
<td>(77)</td>
<td>938</td>
<td>206</td>
<td>(3)</td>
<td>(324)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-process research and development</td>
<td>6</td>
<td></td>
<td></td>
<td>(6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restructuring</td>
<td>119</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provision for taxes on income</td>
<td>1,027</td>
<td>363</td>
<td>143</td>
<td>43</td>
<td>7</td>
<td>(47)</td>
<td>9</td>
<td>434</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Net Earnings</td>
<td>9,422</td>
<td>1,882</td>
<td>590</td>
<td>190</td>
<td>90</td>
<td>(940)</td>
<td>42</td>
<td>(434)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10,600</td>
</tr>
<tr>
<td></td>
<td>Six Months</td>
<td>Intangible asset amortization</td>
<td>Litigation expense, net</td>
<td>In-process research and development</td>
<td>Restructuring related</td>
<td>Acquisition related</td>
<td>Unrealized (loss)/gain on securities</td>
<td>Medical Device Regulation</td>
<td>Tax legislation and related impacts</td>
<td>Other</td>
<td>Six Months</td>
</tr>
<tr>
<td></td>
<td>June 30, 2019</td>
<td>GAAP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>June 30, 2019</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$ 13,555</td>
<td>(2,210)</td>
<td></td>
<td>(84)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GAAP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Other (Income) / Expense</td>
<td>(1,705)</td>
<td>(38)</td>
<td>(832)</td>
<td>(78)</td>
<td>(122)</td>
<td>306</td>
<td></td>
<td>(2,469)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In-process research and development</td>
<td>890</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13,284</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Restructuring</td>
<td>93</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,870</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provision for taxes on income</td>
<td>2,107</td>
<td>423</td>
<td>148</td>
<td>187</td>
<td>12</td>
<td>(64)</td>
<td>16</td>
<td>(242)</td>
<td>12,611</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Net Earnings</td>
<td>9,356</td>
<td>1,825</td>
<td>684</td>
<td>703</td>
<td>191</td>
<td>110</td>
<td>(242)</td>
<td>(14)</td>
<td></td>
</tr>
</tbody>
</table>

(1) Primarily includes a $983 million Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.